Ayala Pharmaceuticals’ preclinical data supports clinical development of AL101 in TripleNegative Breast Cancer (TNBC) tumors bearing Notch mutation
– Ongoing Phase 2 ACCURACY study to explore AL101 and its effect on tumor growth inhibition in people with Adenoid
Global pulmonary embolism therapeutics market to post 9% CAGR over next five years
The global pulmonary embolism therapeutics market is expected to post aCAGR of more than 9% during the period 2019-2023, according to thelatest market research report by Technavio.
R&D in the biopharmaceutical industry is witnessing an upsurge
The traditional R&D in the biopharmaceutical industry iswitnessing an upsurge, due to drug development research, which ishelping in the augmentation of the industrial microbiology market.
Teva launches generic Delzicol delayed-release capsules in the United States
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) todayannounced the launch of a generic version of Delzicol®1(mesalamine) delayed-release capsules, 400 mg, in the U.S.
Global oligonucleotide synthesis market could reach $2.9billion by 2024
Global oligonucleotide synthesis market is expected to reach $2.9billion by 2024, at a CAGR of 10.5% during the forecast period of 2019to 2024.
Influenza Vaccines Market projected to exceed $6 Billion by 2025
The global influenza vaccines market size is expected to surpass USD 6billion by 2025.
Teva launches generic Tarceva (erlotinib) tablets in the United States
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) has launched a generic version of Tarceva®1(erlotinib) tablets, 100 and 150 mg, in the U.S.
Global Opioids Market – Rising Focus on Abuse-deterrent Formulation (ADF) by Generic Manufacturers
Due to an increase in the incidence of medical ailments, the marketstudied is expected to grow over the forecast period.
The $3.12Bn Global Food Enzymes Market by Source, Type, Form, Application and Geography – Forecast to 2024
The global food enzymes market is expected to grow at a CAGR of 7.5%from 2019 to reach $3,125.1 million by 2024 from $2,176.9 million in2019.
Takeda sells Xiidra to Novartis for up to $5.3B, TachoSil to Ethicon for $400M
Takeda sells Xiidra to Novartis for up to$5.3 billion, TachoSil to Ethicon for approximately $400 million